Myeloperoxidase inhibitors as potential drugs

Current Drug Metabolism

Volumn 16, Issue 3, 2015, Pages 168-190

  Lazarević Pašti, Tamara ^a   Leskovac, Andreja ^a   Vasić, Vesna ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Atherosclerosis; Cardiovascular; Inflammation; Inhibitors; Myeloperoxidase; Therapeutics

Indexed keywords

BENZOIC ACID DERIVATIVE; ENZYME INHIBITOR; HYDRAZIDE DERIVATIVE; HYDROXAMIC ACID; INDOLE DERIVATIVE; MYELOPEROXIDASE; NATURAL PRODUCT; OXIDIZING AGENT; PEROXIDASE; PESTICIDE; TRYPTAMINE DERIVATIVE; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLORINATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HOST RESISTANCE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY DISEASE; PHAGOCYTE; PHAGOCYTOSIS; PHAGOLYSOSOME; REACTION ANALYSIS; TISSUE INJURY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION;

BIOMARKERS; ENZYME INHIBITORS; MODELS, MOLECULAR; PEROXIDASE; PROTEIN CONFORMATION;

EID: 84940877224     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021603150812120640     Document Type: Article

References (283)

1. Agner, K. Verdoperoxidase. A ferment isolated from leukocytes. Acta Physiol. Scand., 1941, 2, 1-62.
2. Malle, E.; Furtmuller, P. G.; Sattler, W.; Obinger, C. Myeloperoxidase: A target for new drug development? Br. J. Pharmacol., 2007, 152 (6), 838-54.
3. Harrison, J. E.; Schultz, J. Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem., 1976, 251 (5), 1371-1374.
4. Klebanoff, S. J. Myeloperoxidase: friend and foe. J. Leukoc. Biol., 2005, 77 (5), 598-625.
5. Koeffler, H. P.; Ranyard, J.; Pertcheck, M. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood, 1985, 65 (2), 484-491.
6. Yamada, M.; Kurahashi, K. Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL- 60 cells. J. Biol. Chem., 1984, 259 (5), 3021-3025.
7. Bos, A.; Wever, R.; Roos, D. Characterization and quantification of the peroxidase in human monocytes. Biochim. Biophys. Acta, 1978, 525 (1), 37-44.
8. Schultz, J.; Kaminker, K. Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch. Biochem. Biophys., 1962, 96, 465-470.
9. Nikulshin, S.; Tolstikova, I.; Bartule, A.; Kviluna, D.; Gravele, D.; Gardovska, D. Intracellular neutrophil myeloperoxidase level in pediatric patients: significant age and gender variability. Int. J. Lab. Hematol., 2015, 37 (1), 120-124.
10. Salmon, S. E.; Cline, M. J.; Schultz, J.; Lehrer, R. I. Myeloperoxidase deficiency. Immunologic study of a genetic leukocyte defect. N. Engl. J. Med., 1970, 282 (5), 250-253.
11. Arnhold, J.; Flemmig, J. Human myeloperoxidase in innate and acquired immunity. Arch. Biochem. Biophys., 2010, 500 (1), 92- 106.
12. Baldus, S.; Heeschen, C.; Meinertz, T.; Zeiher, A. M.; Eiserich, J. P.; Munzel, T.; Simoons, M. L.; Hamm, C. W. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003, 108 (12), 1440-1445.
13. Fiedler, T. J.; Davey, C. A.; Fenna, R. E. X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution. J. Biol. Chem., 2000, 275 (16), 11964-11971.
14. Muller, I.; Munder, M.; Kropf, P.; Hansch, G. M. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol., 2009, 30 (11), 522-530.
15. Segal, A. W. How neutrophils kill microbes. Annu. Rev. Immunol., 2005, 23 (1), 197-223.
16. Hampton, M. B.; Kettle, A. J.; Winterbourn, C. C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood, 1998, 92 (9), 3007-3017.
17. Daugherty, A.; Dunn, J. L.; Rateri, D. L.; Heinecke, J. W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Investig., 1994, 94 (1), 437-444.
18. Malle, E.; Marsche, G.; Panzenboeck, U.; Sattler, W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: Fingerprints of newly recognized potential proatherogenic lipoproteins. Arch. Biochem. Biophys., 2006, 445 (2), 245-255.
19. Green, P. S.; Mendez, A. J.; Jacob, J. S.; Crowley, J. R.; Growdon, W.; Hyman, B. T.; Heinecke, J. W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem., 2004, 90 (3), 724-733.
20. Maki, R. A.; Tyurin, V. A.; Lyon, R. C.; Hamilton, R. L.; Dekosky, S. T.; Kagan, V. E.; Reynolds, W. F. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J. Biol. Chem., 2009, 284 (5), 3158-3169.
21. Choi, D. K.; Pennathur, S.; Perier, C.; Tieu, K.; Teismann, P.; Wu, D. C.; Jackson-Lewis, V.; Vila, M.; Vonsattel, J. P.; Heinecke, J. W.; Przedborski, S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci., 2005, 25 (28), 6594-6600.
22. Nagra, R. M.; Becher, B.; Tourtellotte, W. W.; Antel, J. P.; Gold, D.; Paladino, T.; Smith, R. A.; Nelson, J. R.; Reynolds, W. F. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J. Neuroimmunol., 1997, 78 (1- 2), 97-107.
23. Edwards, S. W.; Hughes, V.; Barlow, J.; Bucknall, R. Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis. Biochem. J., 1988, 250 (1), 81-85.
24. Nurcombe, H. L.; Bucknall, R. C.; Edwards, S. W. Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann. Rheum. Dis., 1991, 50 (4), 237-242.
25. Schiller, J.; Arnhold, J.; Sonntag, K.; Arnold, K. NMR studies on human, pathologically changed synovial fluids: Role of hypochlorous acid. Magn. Reson. Med., 1996, 35 (6), 848-853.
26. Malle, E.; Buch, T.; Grone, H. J. Myeloperoxidase in kidney disease. Kidney Int., 2003, 64 (6), 1956-1967.
27. Malle, E.; Woenckhaus, C.; Waeg, G.; Esterbauer, H.; Grone, E. F.; Grone, H. J. Immunological evidence for hypochlorite-modified proteins in human kidney. Am. J. Pathol., 1997, 150 (2), 603-615.
28. Hanumegowda, U. M.; Copple, B. L.; Shibuya, M.; Malle, E.; Ganey, P. E.; Roth, R. A. Basement membrane and matrix metalloproteinases in monocrotaline-induced liver injury. Toxicol. Sci., 2003, 76 (1), 237-246.
29. Nicholls, S. J.; Hazen, S. L. Myeloperoxidase and cardiovascular disease. Arterioscler., Thromb., Vasc. Biol., 2005, 25 (6), 1102- 1111.
30. Vita, J. A.; Brennan, M. L.; Gokce, N.; Mann, S. A.; Goormastic, M.; Shishehbor, M. H.; Penn, M. S.; Keaney Jr, J. F.; Hazen, S. L. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation, 2004, 110 (9), 1134-1139.
31. Zhang, R.; Brennan, M. L.; Fu, X.; Aviles, R. J.; Pearce, G. L.; Penn, M. S.; Topol, E. J.; Sprecher, D. L.; Hazen, S. L. Association between myeloperoxidase levels and risk of coronary artery disease. J. Amer. Med. Assoc., 2001, 286 (17), 2136-2142.
32. Soubhye, J.; Aldib, I.; Elfving, B.; Gelbcke, M.; Furtmuller, P. G.; Podrecca, M.; Conotte, R.; Colet, J.-M.; Rousseau, A.; Reye, F.; Sarakbi, A.; Vanhaeverbeek, M.; Kauffmann, J.-M.; Obinger, C.; Nee, J.; Prevost, M.; Zouaoui Boudjeltia, K.; Dufrasne, F.; Van Antwerpen, P. Design, Synthesis, and Structure-Activity Relationship Studies of Novel 3-Alkylindole Derivatives as Selective and Highly Potent Myeloperoxidase Inhibitors. J. Med. Chem., 2013, 56 (10), 3943-3958.
33. Kettle, A. J.; Gedye, C. A.; Winterbourn, C. C. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem. J., 1997, 321 ( Pt 2), 503-508.
34. Liu, C.; Desikan, R.; Ying, Z.; Gushchina, L.; Kampfrath, T.; Deiuliis, J.; Wang, A.; Xu, X.; Zhong, J.; Rao, X.; Sun, Q.; Maiseyeu, A.; Parthasarathy, S.; Rajagopalan, S. Effects of a novel pharmacologic inhibitor of myeloperoxidase in a mouse atherosclerosis model. PLoS One, 2012, 7 (12), e50767.
35. Shiba, Y.; Kinoshita, T.; Chuman, H.; Taketani, Y.; Takeda, E.; Kato, Y.; Naito, M.; Kawabata, K.; Ishisaka, A.; Terao, J.; Kawai, Y. Flavonoids as Substrates and Inhibitors of Myeloperoxidase: Molecular Actions of Aglycone and Metabolites. Chem. Res. Toxicol., 2008, 21 (8), 1600-1609.
36. Sies, H.; Schewe, T.; Heiss, C.; Kelm, M. Cocoa polyphenols and inflammatory mediators. Am. J. Clin. Nutr., 2005, 81 (1), 304S- 312S.
37. Galijasevic, S.; Abdulhamid, I.; Abu-Soud, H. M. Melatonin Is a Potent Inhibitor for Myeloperoxidase. Biochemistry, 2008, 47 (8), 2668-2677.
38. Hanson, S.; Nordvall, G.; Tiden, A. K. Preparation of xanthinethione derivatives as myeloperoxidase inhibitors. WO 2003089430 A1, 2003.
39. Ikeda-Saito, M.; Shelley, D. A.; Lu, L.; Booth, K. S.; Caughey, W. S.; Kimura, S. Salicylhydroxamic acid inhibits myeloperoxidase activity. J. Biol. Chem., 1991, 266 (6), 3611-3616.
40. Kettle, A. J.; Gedye, C. A.; Hampton, M. B.; Winterbourn, C. C. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem. J., 1995, 308 ( Pt 2), 559-563.
41. Neve, J.; Parij, N.; Moguilevsky, N. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal antiinflammatory drugs investigated with a human recombinant enzyme. Eur. J. Pharmacol., 2001, 417 (1-2), 37-43.
42. Regasini, L. O.; Vellosa, J. C. R.; Silva, D. H. S.; Furlan, M.; de Oliveira, O. M. M.; Khalil, N. M.; Brunetti, I. L.; Young, M. C. M.; Barreiro, E. J.; Bolzani, V. S. Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry, 2008, 69 (8), 1739-1744.
43. Soubhye, J.; Prevost, M.; Van Antwerpen, P.; Zouaoui Boudjeltia, K.; Rousseau, A.; Furtmuller, P. G.; Obinger, C.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J.; Gelbcke, M.; Dufrasne, F. O. Structurebased design, synthesis, and pharmacological evaluation of 3- (aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. J. Med. Chem., 2010, 53 (24), 8747-8759.
44. Van Antwerpen, P.; Dufrasne, F.; Lequeux, M.; Boudjeltia, K. Z.; Lessgyer, I.; Babar, S.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal antiinflammatory drugs: flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid. Eur. J. Pharmacol., 2007, 570 (1-3), 235-243.
45. Van Antwerpen, P.; Moreau, P.; Zouaoui Boudjeltia, K.; Babar, S.; Dufrasne, F.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J. Development and validation of a screening procedure for the assessment of inhibition using a recombinant enzyme. Talanta, 2008, 75 (2), 503-510.
46. Van Antwerpen, P.; Prevost, M.; Zouaoui-Boudjeltia, K.; Babar, S.; Legssyer, I.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J.; Dufrasne, F. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification. Bioorg. Med. Chem., 2008, 16 (4), 1702-1720.
47. Ximenes, V. F.; Paino, I. M.; Faria-Oliveira, O. M.; Fonseca, L. M.; Brunetti, I. L. Indole ring oxidation by activated leukocytes prevents the production of hypochlorous acid. Braz. J. Med. Biol. Res., 2005, 38 (11), 1575-1583.
48. Akin, D. T.; Kinkade, J. M. Jr. Processing of a newly identified intermediate of human myeloperoxidase in isolated granules occurs at neutral pH. J. Biol. Chem., 1986, 261 (18), 8370-8375.
49. Furtmuller, P. G.; Zederbauer, M.; Jantschko, W.; Helm, J.; Bogner, M.; Jakopitsch, C.; Obinger, C. Active site structure and catalytic mechanisms of human peroxidases. Arch. Biochem. Biophys., 2006, 445 (2), 199-213.
50. Wever, R.; Plat, H. Spectral properties of myeloperoxidase and its ligand complexes. Biochim. Biophys. Acta, 1981, 661 (2), 235-239.
51. Andrews, P. C.; Krinsky, N. I. The reductive cleavage of myeloperoxidase in half, producing enzymically active hemimyeloperoxidase. J. Biol. Chem., 1981, 256 (9), 4211-4218.
52. Andrews, P. C.; Parnes, C.; Krinsky, N. I. Comparison of myeloperoxidase and hemi-myeloperoxidase with respect to catalysis, regulation, and bactericidal activity. Arch. Biochem. Biophys., 1984, 228 (2), 439-442.
53. Oxvig, C.; Thomsen, A. R.; Overgaard, M. T.; Sorensen, E. S.; Hojrup, P.; Bjerrum, M. J.; Gleich, G. J.; Sottrup-Jensen, L. Biochemical evidence for heme linkage through esters with Asp-93 and Glu-241 in human eosinophil peroxidase. The ester with Asp- 93 is only partially formed in vivo. J. Biol. Chem., 1999, 274 (24), 16953-16958.
54. Singh, A. K.; Singh, N.; Sharma, S.; Singh, S. B.; Kaur, P.; Bhushan, A.; Srinivasan, A.; Singh, T. P. Crystal Structure of Lactoperoxidase at 2.4 A Resolution. J. Mol. Biol., 2008, 376 (4), 1060-1075.
55. Dolphin, D.; Forman, A.; Borg, D. C.; Fajer, J.; Felton, R. H. Compounds I of catalase and horse radish peroxidase: pi-cation radicals. Proc. Natl. Acad. Sci. U. S. A., 1971, 68 (3), 614-618.
56. Van Dalen, C. J.; Whitehouse, M. W.; Winterbourn, C. C.; Kettle, A. J. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem. J., 1997, 327 (2), 487-492.
57. Burner, U.; Furtmuller, P. G.; Kettle, A. J.; Koppenol, W. H.; Obinger, C. Mechanism of reaction of myeloperoxidase with nitrite. J. Biol. Chem., 2000, 275 (27), 20597-20601.
58. Burner, U.; Jantschko, W.; Obinger, C. Kinetics of oxidation of aliphatic and aromatic thiols by myeloperoxidase compounds I and II. FEBS Lett., 1999, 443 (3), 290-296.
59. Furtmuller, P. G.; Burner, U.; Jantschko, W.; Regelsberger, G.; Obinger, C. Two-electron reduction and one-electron oxidation of organic hydroperoxides by human myeloperoxidase. FEBS Lett., 2000, 484 (2), 139-143.
60. Jantschko, W.; Furtmuller, P. G.; Allegra, M.; Livrea, M. A.; Jakopitsch, C.; Regelsberger, G.; Obinger, C. Redox Intermediates of Plant and Mammalian Peroxidases: A Comparative Transient- Kinetic Study of Their Reactivity Toward Indole Derivatives. Arch. Biochem. Biophys., 2002, 398 (1), 12-22.
61. Lazarevic-Pasti, T.; Colovic, M.; Savic, J.; Momic, T.; Vasic, V. Oxidation of diazinon and malathion by myeloperoxidase. Pestic. Biochem. Physiol., 2011, 100 (2), 140-144.
62. Lazarevic-Pasti, T.; Momic, T.; Radojevic, M.; Vasic, V. Influence of organophosphorus pesticides on peroxidase and chlorination activity of human myeloperoxidase. Pestic. Biochem. Physiol., 2013, 107 (1), 55-60.
63. Lazarevic-Pasti, T.; Momis, T.; Onjia, A.; Vujisic, L.; Vasic, V. Myeloperoxidase-mediated oxidation of organophosphorus pesticides as a pre-step in their determination by AChE based bioanalytical methods. Microchim. Acta, 2010, 170 (3-4), 289-297.
64. Lazarevic-Pasti, T.; Nastasijevic, B.; Vasic, V. Oxidation of chlorpyrifos, azinphos-methyl and phorate by myeloperoxidase. Pestic. Biochem. Physiol., 2011, 101 (3), 220-226.
65. Marquez, L. A.; Dunford, H. B. Kinetics of oxidation of tyrosine and dityrosine by myeloperoxidase compounds I and II: Implications for lipoprotein peroxidation studies. J. Biol. Chem., 1995, 270 (51), 30434-30440.
66. Kettle, A. J.; Winterbourn, C. C. Myeloperoxidase: A key regulator of neutrophil oxidant product. Redox Rep., 1997, 3 (1), 3-15.
67. Hoogland, H.; van Kuilenburg, A.; van Riel, C.; Muijsers, A. O.; Wever, R. Spectral properties of myeloperoxidase Compounds II and III. Biochim. Biophys. Acta, 1987, 916 (1), 76-82.
68. Andrews, P. C.; Krinsky, N. I. A kinetic analysis of the interaction of human myeloperoxidase with hydrogen peroxide, chloride ions, and protons. J. Biol. Chem., 1982, 257 (22), 13240-13245.
69. Lessig, J.; Schiller, J.; Arnhold, J.; Fuchs, B. Hypochlorous acidmediated generation of glycerophosphocholine from unsaturated plasmalogen glycerophosphocholine lipids. J. Lipid Res., 2007, 48 (6), 1316-1324.
70. Malle, E.; Marsche, G.; Arnhold, J.; Davies, M. J. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta, 2006, 1761 (4), 392-415.
71. Thukkani, A. K.; McHowat, J.; Hsu, F. F.; Brennan, M. L.; Hazen, S. L.; Ford, D. A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation, 2003, 108 (25), 3128-3133.
72. Thukkani, A. K.; Martinson, B. D.; Albert, C. J.; Vogler, G. A.; Ford, D. A. Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-ClHDA-mediated myocardial injury. Am. J. Physiol. Heart Circ. Physiol., 2005, 288 (6), H2955-H2964.
73. Marsche, G.; Heller, R.; Fauler, G.; Kovacevic, A.; Nuszkowski, A.; Graier, W.; Sattler, W.; Malle, E. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler., Thromb., Vasc. Biol., 2004, 24 (12), 2302-2306.
74. Eiserich, J. P.; Baldus, S.; Brennan, M.-L.; Ma, W.; Zhang, C.; Tousson, A.; Castro, L.; Lusis, A. J.; Nauseef, W. M.; White, C. R.; Freeman, B. A. Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase. Science, 2002, 296 (5577), 2391-2394.
75. Takeshita, J.; Byun, J.; Nhan, T. Q.; Pritchard, D. K.; Pennathur, S.; Schwartz, S. M.; Chait, A.; Heinecke, J. W. Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue: A potential pathway for somatic mutagenesis by macrophages. J. Biol. Chem., 2006, 281 (6), 3096-3104.
76. Hazen, S. L.; Hsu, F. F.; Mueller, D. M.; Crowley, J. R.; Heinecke, J. W. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J. Clin. Investig., 1996, 98 (6), 1283-1289.
77. Hazen, S. L.; Heinecke, J. W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Investig., 1997, 99 (9), 2075-2081.
78. Zheng, L.; Nukuna, B.; Brennan, M. L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P. L.; Ischiropoulos, H.; Smith, J. D.; Kinter, M.; Hazen, S. L. Apolipoprotein A-I is a selective target for myeloperoxidasecatalyzed oxidation and function impairment in subjects with cardiovascular disease. J. Clin. Investig., 2004, 114 (4), 529-541.
79. Buss, I. H.; Senthilmohan, R.; Darlow, B. A.; Mogridge, N.; Kettle, A. J.; Winterbourn, C. C. 3-Chlorotyrosine as a Marker of Protein Damage by Myeloperoxidase in Tracheal Aspirates From Preterm Infants: Association With Adverse Respiratory Outcome. Pediatr. Res., 2003, 53 (3), 455-462.
80. Kettle, A. J.; Chan, T.; Osberg, I.; Senthilmohan, R.; Chapman, A. L.; Mocatta, T. J.; Wagener, J. S. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am. J. Respir. Crit. Care. Med., 2004, 170 (12), 1317-1323.
81. Gujral, J. S.; Liu, J.; Farhood, A.; Hinson, J. A.; Jaeschke, H. Functional importance of ICAM-1 in the mechanism of neutrophilinduced liver injury in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286 (3), 499-507.
82. Grone, H. J.; Grone, E. F.; Malle, E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab. Investig., 2002, 82 (1), 5-14.
83. Malle, E.; Hazell, L.; Stocker, R.; Sattler, W.; Esterbauer, H.; Waeg, G. Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler., Thromb., Vasc. Biol., 1995, 15 (7), 982-989.
84. Hasegawa, T.; Malle, E.; Farhood, A.; Jaeschke, H. Generation of hypochlorite-modified proteins by neutrophils during ischemiareperfusion injury in rat liver: Attenuation by ischemic preconditioning. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289 (4), G760-G767.
85. Hazell, L. J.; Arnold, L.; Flowers, D.; Waeg, G.; Malle, E.; Stocker, R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Investig., 1996, 97 (6), 1535-1544.
86. Malle, E.; Waeg, G.; Schreiber, R.; Grone, E. F.; Sattler, W.; Grone, H. J. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochloritemodified proteins. Eur. J. Biochem., 2000, 267 (14), 4495-503.
87. Marsche, G.; Levak-Frank, S.; Quehenberger, O.; Heller, R.; Sattler, W.; Malle, E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J., 2001, 15 (6), 1095-1097.
88. Marsche, G.; Zimmermann, R.; Horiuchi, S.; Tandon, N. N.; Sattler, W.; Malle, E. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J. Biol. Chem., 2003, 278 (48), 47562-47570.
89. Hawkins, C. L.; Davies, M. J. Hypochlorite-induced damage to proteins: formation of nitrogen-centred radicals from lysine residues and their role in protein fragmentation. Biochem. J., 1998, 332, 617-625.
90. Panasenko, O. M.; Arnhold, J.; Vladimirov Yu, A.; Arnhold, K.; Sergienko, V. I. Hypochlorite-induced peroxidation of egg yolk phosphatidylcholine is mediated by hydroperoxides. Free Radic. Res., 1997, 27 (1), 1-12.
91. Miyamoto, S.; Martinez, G. R.; Rettori, D.; Augusto, O.; Medeiros, M. H.; Di Mascio, P. Linoleic acid hydroperoxide reacts with hypochlorous acid, generating peroxyl radical intermediates and singlet molecular oxygen. Proc. Natl. Acad. Sci. U. S. A., 2006, 103 (2), 293-298.
92. Wiersma, J. J.; Meuwese, M. C.; van Miert, J. N.; Kastelein, A.; Tijssen, J. G.; Piek, J. J.; Trip, M. D. Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. Med. Sci. Monit., 2008, 14 (8), CR406-CR410.
93. Malicka, B.; Kaczmarek, U.; Skoskiewicz-Malinowska, K. Selected antibacterial factors in the saliva of diabetic patients. Arch. Oral Biol., 2015, 60 (3), 425-431.
94. Lefkowitz, D. L.; Lefkowitz, S. S. Microglia and myeloperoxidase: A deadly partnership in neurodegenerative disease. Free Radic. Biol. Med., 2008, 45 (5), 726-31.
95. Borges, F. K.; Stella, S. F.; Souza, J. F.; Wendland, A. E.; Werres Junior, L. C.; Ribeiro, J. P.; Polanczyk, C. A. Serial analyses of Creactive protein and myeloperoxidase in acute coronary syndrome. Clin. Cardiol., 2009, 32 (11), E58-E62.
96. Zakynthinos, E.; Pappa, N. Inflammatory biomarkers in coronary artery disease. J. Cardiol., 2009, 53 (3), 317-333.
97. Loria, V.; Dato, I.; Graziani, F.; Biasucci, L. M. Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediat. Inflamm., 2008, 2008, 135625.
98. Mathew, A.; Taranalli, A. D.; Torgal, S. S. Evaluation of antiinflammatory and wound healing activity of Gentiana lutea rhizome extracts in animals. Pharm. Biol., 2004, 42 (1), 8-12.
99. Wu, A. H. Novel biomarkers of cardiovascular disease: myeloperoxidase for acute and/or chronic heart failure? Clin. Chem., 2009, 55 (1), 12-14.
100. Brennan, M. L.; Penn, M. S.; Van Lente, F.; Nambi, V.; Shishehbor, M. H.; Aviles, R. J.; Goormastic, M.; Pepoy, M. L.; McErlean, E. S.; Topol, E. J.; Nissen, S. E.; Hazen, S. L. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med., 2003, 349 (17), 1595-1604.
101. Babior, B. M.; Curnutte, J. T.; McMurrich, B. J. The particulate superoxide forming system from human neutrophils. Properties of the system and further evidence supporting its participation in the respiratory burst. J. Clin. Investig., 1976, 58 (4), 989-996.
102. Sengeloev, H.; Kjeldsen, L.; Borregaard, N. Control of exocytosis in early neutrophil activation. J. Immunol., 1993, 150 (4), 1535- 1543.
103. Kothari, N.; Keshari, R. S.; Bogra, J.; Kohli, M.; Abbas, H.; Malik, A.; Dikshit, M.; Barthwal, M. K. Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J. Crit. Care, 2011, 26 (4), 435.e1-435.e7.
104. Krawisz, J. E.; Sharon, P.; Stenson, W. F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology, 1984, 87 (6), 1344-1350.
105. Dhiman, M.; Estrada-Franco, J. G.; Pando, J. M.; Ramirez-Aguilar, F. J.; Spratt, H.; Vazquez-Corzo, S.; Perez-Molina, G.; Gallegos- Sandoval, R.; Moreno, R.; Garg, N. J. Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas' disease. Clin. Vaccine Immunol., 2009, 16 (5), 660-666.
106. Hoskin, T. S. Neutrophil Activation in Inflammatory Bowel Disease. BSc Thesis, University of Otago: Christchurch, 2011.
107. Hajnsek, M.; Schiffer, D.; Harrich, D.; Koller, D.; Verient, V.; Palen, J. v. d.; Heinzle, A.; Binder, B.; Sigl, E.; Sinner, F.; Guebitz, G. M. An electrochemical sensor for fast detection of wound infection based on myeloperoxidase activity. Sens. Actuator B-Chem., 2015, 209, 265-274.
108. Roman, R. M.; Wendland, A. E.; Polanczyk, C. A. Myeloperoxidase and coronary arterial disease: from research to clinical practice. Arq. Bras. Cardiol., 2008, 91 (1), e11-e19.
109. Nambi, V. The use of myeloperoxidase as a risk marker for atherosclerosis. Curr. Atheroscler. Rep., 2005, 7 (2), 127-131.
110. Smith, J. D. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J. Clin. Lipidol., 2010, 4 (5), 382-388.
111. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P. Current role of myeloperoxidase in routine clinical practice. Expert Rev. Cardiovasc. Ther., 2011, 9 (2), 223-230.
112. Niccoli, G.; Dato, I.; Crea, F. Myeloperoxidase May Help to Differentiate Coronary Plaque Erosion From Plaque Rupture in Patients With Acute Coronary Syndromes. Trends Cardiovasc. Med., 2010, 20 (8), 276-281.
113. Olza, J.; Aguilera, C. M.; Gil-Campos, M.; Leis, R.; Bueno, G.; Martinez-Jimenez, M. D.; Valle, M.; Canete, R.; Tojo, R.; Moreno, L. A.; Gil, A. Myeloperoxidase Is an Early Biomarker of Inflammation and Cardiovascular Risk in Prepubertal Obese Children. Diabetes Care, 2012, 35 (11), 2373-2376.
114. Jialal, I. Contemporary scientific insights: Role of biomarkers of inflammation in cardiovascular disease/atherosclerosis. Crit. Pathw. Cardiol., 2006, 5 (4), 191-210.
115. Emami Razavi, A.; Basati, G.; Varshosaz, J.; Abdi, S. Association between HDL Particles Size and Myeloperoxidase/Paraoxonase-1 (MPO/PON1) Ratio in Patients with Acute Coronary Syndrome. Acta Med. Iran., 2013, 51 (6), 365-371.
116. Huang, Y.; Wu, Z.; Riwanto, M.; Gao, S.; Levison, B. S.; Gu, X.; Fu, X.; Wagner, M. A.; Besler, C.; Gerstenecker, G.; Zhang, R.; Li, X.-M.; DiDonato, A. J.; Gogonea, V.; Tang, W. H. W.; Smith, J. D.; Plow, E. F.; Fox, P. L.; Shih, D. M.; Lusis, A. J.; Fisher, E. A.; DiDonato, J. A.; Landmesser, U.; Hazen, S. L. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest., 2013, 123 (9), 3815-3828.
117. Klebanoff, S. J. Myeloperoxidase. Proc. Assoc. Am. Physicians 1999, 111 (5), 383-9.
118. Besler, C.; Heinrich, K.; Rohrer, L.; Doerries, C.; Riwanto, M.; Shih, D. M.; Chroni, A.; Yonekawa, K.; Stein, S.; Schaefer, N.; Mueller, M.; Akhmedov, A.; Daniil, G.; Manes, C.; Templin, C.; Wyss, C.; Maier, W.; Tanner, F. C.; Matter, C. M.; Corti, R.; Furlong, C.; Lusis, A. J.; von Eckardstein, A.; Fogelman, A. M.; Luscher, T. F.; Landmesser, U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest., 2011, 121 (7), 2693-2708.
119. Davidson, W. S.; Silva, R. A. G. D.; Chantepie, S.; Lagor, W. R.; Chapman, M. J.; Kontush, A. Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function. Arterioscler., Thromb., Vasc. Biol., 2009, 29 (6), 870-876.
120. Abbott, C. A.; Mackness, M. I.; Kumar, S.; Boulton, A. J.; Durrington, P. N. Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins. Arterioscler., Thromb., Vasc. Biol., 1995, 15 (11), 1812-1818.
121. Mackness, M. I.; Arrol, S.; Durrington, P. N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett., 1991, 286 (1-2), 152-4.
122. Bhattacharyya, T.; Nicholls, S. J.; Topol, E. J.; et al. RElationship of paraoxonase 1 (pon1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA, 2008, 299 (11), 1265-1276.
123. Rozenberg, O.; Shih, D. M.; Aviram, M. Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol Biosynthesis: Possible Role for Its Phospholipase-A2â"Like Activity and Lysophosphatidylcholine Formation. Arterioscler., Thromb., Vasc. Biol., 2003, 23 (3), 461-467.
124. Wang, F.; Liu, Y.; Cong, Y.; Li, P.; Li, Y.; Yan, Z.; Tang, Y.; Cheng, Y.; Zheng, Y. Shift of the interconnection from the reaction system of paraoxonase 1 to the peroxidation reaction system of myeloperoxidase with HDL-C levels: A marker of atherosclerosis in patients with normal cholesterol levels. Clin. Chim. Acta, 2015, 438, 370-375.
125. Katakami, N.; Kaneto, H.; Matsuoka, T. A.; Takahara, M.; Osonoi, T.; Saitou, M.; Kawai, K.; Ishibashi, F.; Kashiwagi, A.; Kawamori, R.; Shimomura, I.; Yamasaki, Y. Accumulation of oxidative stressrelated gene polymorphisms and the risk of coronary heart disease events in patients with type 2 diabetes-an 8-year prospective study. Atherosclerosis, 2014, 235 (2), 408-414.
126. Armstrong, E. J.; Morrow, D. A.; Sabatine, M. S. Inflammatory Biomarkers in Acute Coronary Syndromes: Part III: Biomarkers of Oxidative Stress and Angiogenic Growth Factors. Circulation, 2006, 113 (8), e289-e292.
127. Gustapane, M.; Cardillo, M. T.; Biasillo, G.; Biasucci, L. M. Myeloperoxidase as possible diagnostic and prognostic marker of acute coronary syndrome. Recenti Prog. Med., 2011, 102 (11), 447- 450.
128. Brennan, M. L.; Hazen, S. L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr. Opin. Lipidol., 2003, 14 (4), 353-359.
129. Buffon, A.; Biasucci, L. M.; Liuzzo, G.; D'Onofrio, G.; Crea, F.; Maseri, A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med., 2002, 347 (1), 5-12.
130. Cavusoglu, E.; Ruwende, C.; Eng, C.; Chopra, V.; Yanamadala, S.; Clark, L. T.; Pinsky, D. J.; Marmur, J. D. Usefulness of Baseline Plasma Myeloperoxidase Levels as an Independent Predictor of Myocardial Infarction at Two Years in Patients Presenting With Acute Coronary Syndrome. Am. J. Cardiol., 2007, 99 (10), 1364- 1368.
131. Karadag, B.; Vatan, B.; Hacioglu, Y.; Duman, D.; Baskurt, M.; Keles, I.; Ongen, Z.; Vural, V. A. Serum myeloperoxidase level predicts reperfusion in patients with myocardial infarction receiving thrombolytic therapy. Heart Vessels, 2009, 24 (4), 247-253.
132. Saetta, M.; Finkelstein, R.; Cosio, M. G. Morphological and cellular basis for airflow limitation in smokers. Eur. Respir. J., 1994, 7 (8), 1505-1515.
133. Amin, K.; Ekberg-Jansson, A.; Lofdahl, C. G.; Venge, P. Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: A biopsy study. Thorax, 2003, 58 (2), 135-142.
134. Betsuyaku, T.; Nishimura, M.; Takeyabu, K.; Tanino, M.; Venge, P.; Xu, S.; Kawakami, Y. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am. J. Respir. Crit. Care. Med., 1999, 159 (6), 1985- 1991.
135. Keatings, V. M.; Barnes, P. J. Granulocyte activation markers in induced sputum: Comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am. J. Respir. Crit. Care. Med., 1997, 155 (2), 449-453.
136. Peleman, R. A.; Rytila, P. H.; Kips, J. C.; Joos, G. F.; Pauwels, R. A. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur. Respir. J., 1999, 13 (4), 839- 843.
137. Saetta, M.; Di Stefano, A.; Turato, G.; Facchini, F. M.; Corbino, L.; Mapp, C. E.; Maestrelli, P.; Ciaccia, A.; Fabbri, L. M. CD8+ Tlymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med., 1998, 157 (31), 822-826.
138. Sin, D. D.; Paul Man, S. F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation, 2003, 107 (11), 1514- 1519.
139. James, A. L.; Knuiman, M. W.; Divitini, M. L.; Musk, A. W.; Ryan, G.; Bartholomew, H. C. Associations between white blood cell count, lung function, respiratory illness and mortality: The Busselton Health Study. Eur. Respir. J., 1999, 13 (5), 1115-1119.
140. Smith, M. R.; Kinmonth, A.-L.; Luben, R. N.; Bingham, S.; Day, N. E.; Wareham, N. J.; Welch, A.; Khaw, K.-T. Smoking status and differential white cell count in men and women in the EPICNorfolk population. Atherosclerosis, 2003, 169 (2), 331-337.
141. Oudijk, E.; Lammers, J. J.; Koenderman, L. Systemic inflammation in chronic obstructive pulmonary disease. Eur. Respir. J., 2003, 22 (46 suppl), 5s-13s.
142. Ekberg-Jansson, A.; Andersson, B.; Bake, B.; Boijsen, M.; Enanden, I.; Rosengren, A.; Skoogh, B. E.; Tylen, U.; Venge, P.; Lofdahl, C. G. Neutrophil-associated activation markers in healthy smokers relates to a fall in DLCO and to emphysematous changes on high resolution CT. Respir. Med., 2001, 95 (5), 363-373.
143. Andelid, K.; Bake, B.; Rak, S.; Linden, A.; Rosengren, A.; Ekberg- Jansson, A. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir. Med., 2007, 101 (5), 888-895.
144. Kettle, A. J. Neutrophils convert tyrosyl residues in albumin to chlorotyrosine. FEBS Lett., 1996, 379 (1), 103-106.
145. Winterbourn, C. C.; Kettle, A. J. Biomarkers of myeloperoxidasederived hypochlorous acid. Free Radic. Biol. Med., 2000, 29 (5), 403-409.
146. Pattison, D. I.; Davies, M. J. Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem. Res. Toxicol., 2001, 14 (10), 1453-1464.
147. Keli, S. O.; Hertog, M. G.; Feskens, E. J.; Kromhout, D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: The Zutphen study. Arch. Intern. Med., 1996, 156 (6), 637-642.
148. Bergt, C.; Pennathur, S.; Fu, X.; Byun, J.; O'Brien, K.; McDonald, T. O.; Singh, P.; Anantharamaiah, G. M.; Chait, A.; Brunzell, J.; Geary, R. L.; Oram, J. F.; Heinecke, J. W. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. U. S. A., 2004, 101 (35), 13032-13037.
149. Shao, B.; Oda, M. N.; Bergt, C.; Fu, X.; Green, P. S.; Brot, N.; Oram, J. F.; Heinecke, J. W. Myeloperoxidase impairs ABCA1- dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem., 2006, 281 (14), 9001-9004.
150. Salavej, P.; Spalteholz, H.; Arnhold, J. Modification of amino acid residues in human serum albumin by myeloperoxidase. Free Radic. Biol. Med., 2006, 40 (3), 516-525.
151. Senthilmohan, R.; Kettle, A. J. Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. Arch. Biochem. Biophys., 2006, 445 (2), 235-244.
152. Wang, Z.; Nicholls, S. J.; Rodriguez, E. R.; Kummu, O.; Horkko, S.; Barnard, J.; Reynolds, W. F.; Topol, E. J.; DiDonato, J. A.; Hazen, S. L. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med., 2007, 13 (10), 1176-1184.
153. Sirpal, S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin. Sci., 2009, 116 (9), 681-695.
154. Baldus, S.; Eiserich, J. P.; Brennan, M. L.; Jackson, R. M.; Alexander, C. B.; Freeman, B. A. Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic. Biol. Med., 2002, 33 (7), 1010-1019.
155. Ischiropoulos, H.; Beckman, J. S. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J. Clin. Investig., 2003, 111 (2), 163-169.
156. Leeuwenburgh, C.; Hardy, M. M.; Hazen, S. L.; Wagner, P.; Ohishi, S.; Steinbrecher, U. P.; Heinecke, J. W. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem., 1997, 272 (3), 1433-1436.
157. Schopfer, F. J.; Baker, P. R. S.; Freeman, B. A. NO-dependent protein nitration: A cell signaling event or an oxidative inflammatory response? Trends Biochem. Sci., 2003, 28 (12), 646- 654.
158. Francis, G. A.; Mendez, A. J.; Bierman, E. L.; Heinecke, J. W. Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells. Proc. Natl. Acad. Sci. U. S. A., 1993, 90 (14), 6631-6635.
159. Heinecke, J. W.; Li, W.; Daehnke Iii, H. L.; Goldstein, J. A. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J. Biol. Chem., 1993, 268 (6), 4069-4077.
160. Albert, C. J.; Crowley, J. R.; Hsu, F. F.; Thukkani, A. K.; Ford, D. A. Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: Identification of 2- chlorohexadecanal. J. Biol. Chem., 2001, 276 (26), 23733-23741.
161. Thukkani, A. K.; Hsu, F. F.; Crowley, J. R.; Wysolmerski, R. B.; Albert, C. J.; Ford, D. A. Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: Production of the chemoattractant, 2-chlorohexadecanal. J. Biol. Chem., 2002, 277 (6), 3842-3849.
162. Zhang, R.; Brennan, M. L.; Shen, Z.; MacPherson, J. C.; Schmitt, D.; Molenda, C. E.; Hazen, S. L. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem., 2002, 277 (48), 46116-46122.
163. Zouaoui Boudjeltia, K.; Moguilevsky, N.; Legssyer, I.; Babar, S.; Guillaume, M.; Delree, P.; Vanhaeverbeek, M.; Brohee, D.; Ducobu, J.; Remacle, C. Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: An additional mechanism to subendothelium oxidation. Biochem. Biophys. Res. Commun., 2004, 325 (2), 434-438.
164. Dunford, H. B. Myeloperoxidase and eosinophil peroxidase: phagocytosis and microbial killing. In Heme Peroxidases, Dunford, H. B., Ed. Wiley-VCH: New York, 1999; pp. 349-385.
165. Furtmuller, P. G.; Arnhold, J.; Jantschko, W.; Pichler, H.; Obinger, C. Redox properties of the couples compound I/compound II and compound II/native enzyme of human myeloperoxidase. Biochem. Biophys. Res. Commun., 2003, 301 (2), 551-557.
166. Jantschko, W.; Furtmuller, P. G.; Zederbauer, M.; Neugschwandtner, K.; Lehner, I.; Jakopitsch, C.; Arnhold, J.; Obinger, C. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design. Biochem. Pharmacol., 2005, 69 (8), 1149-1157.
167. Yang, X. X.; Hu, Z. P.; Chan, S. Y.; Zhou, S. F. Monitoring drugprotein interaction. Clin. Chim. Acta, 2006, 365 (1-2), 9-29.
168. Kubow, S.; Wells, P. G. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol. Pharmacol., 1989, 35 (4), 504-511.
169. Mays, D. C.; Pawluk, L. J.; Apseloff, G.; Davis, W. B.; She, Z. W.; Sagone, A. L.; Gerber, N. Metabolism of phenytoin and covalent binding of reactive intermediates in activated human neutrophils. Biochem. Pharmacol., 1995, 50 (3), 367-380.
170. Uetrecht, J.; Zahid, N. N-chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem. Res. Toxicol., 1988, 1 (3), 148-151.
171. Furst, S. M.; Uetrecht, J. P. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem. Pharmacol., 1993, 45 (6), 1267-1275.
172. Nappi, A. J.; Vass, E. The effects of nitric oxide on the oxidations of l-dopa and dopamine mediated by tyrosinase and peroxidase. J. Biol. Chem., 2001, 276 (14), 11214-11222.
173. Uetrecht, J.; Zahid, N.; Tehim, A.; Fu, J. M.; Rakhit, S. Structural features associated with reactive metabolite formation in clozapine analogues. Chem-Biol. Interact., 1997, 104 (2-3), 117-129.
174. Williams, D. P.; Pirmohamed, M.; Naisbitt, D. J.; Maggs, J. L.; Park, B. K. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther., 1997, 283 (3), 1375-1382.
175. Lai, W. G.; Zahid, N.; Uetrecht, J. P. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther., 1999, 291 (1), 292-299.
176. Lai, W. G.; Gardner, I.; Zahid, N.; Uetrecht, J. P. Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. Drug Metab. Dispos., 2000, 28 (3), 255-263.
177. Uetrecht, J. P.; Zahid, N. N-Chlorination and oxidation of procainamide by myeloperoxidase: Toxicological implications. Chem. Res. Toxicol., 1991, 4 (2), 218-222.
178. Miyamoto, G.; Zahid, N.; Uetrecht, J. P. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol., 1997, 10 (4), 414-419.
179. Nastasijevic, B.; Lazarevic-Pasti, T.; Dimitrijevic-Brankovic, S.; Pasti, I.; Vujacic, A.; Joksic, G.; Vasic, V. Inhibition of myeloperoxidase and antioxidative activity of Gentiana lutea extracts. J. Pharm. Biomed. Anal., 2012, 66, 191-196.
180. Bolscher, B. G. J. M.; Wever, R. A kinetic study of the reaction between human myeloperoxidase, hydroperoxides and cyanide. Inhibition by chloride and thiocyanate. Biochim. Biophys. Acta, 1984, 788 (1), 1-10.
181. Bakkenist, A. R. J.; De Boer, J. E. G.; Plat, H.; Wever, R. The halide complexes of myeloperoxidase and the mechanism of the halogenation reactions. Biochim. Biophys. Acta, 1980, 613 (2), 337- 348.
182. Ikeda-Saito, M. A study of ligand binding to spleen myeloperoxidase. Biochemistry, 1987, 26 (14), 4344-4349.
183. Abu-Soud, H. M.; Hazen, S. L. Nitric oxide modulates the catalytic activity of myeloperoxidase. J. Biol. Chem., 2000, 275 (8), 5425- 5430.
184. Abu-Soud, H. M.; Hazen, S. L. Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem., 2000, 275 (48), 37524-37532.
185. Blair-Johnson, M.; Fiedler, T.; Fenna, R. Human myeloperoxidase: Structure of a cyanide complex and its interaction with bromide and thiocyanate substrates at 1.9 A resolution. Biochemistry, 2001, 40 (46), 13990-13997.
186. Evans, T. J.; Buttery, L. D. K.; Carpenter, A.; Springall, D. R.; Polak, J. M.; Cohen, J. Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria. Proc. Natl. Acad. Sci. U. S. A., 1996, 93 (18), 9553-9558.
187. MacMicking, J.; Xie, Q. W.; Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol., 1997, 15, 323-350.
188. Weinberg, J. B. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: A review. Mol. Med., 1998, 4 (9), 557-591.
189. Leone, A. M.; Francis, P. L.; Rhodes, P.; Moncada, S. A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem. Biophys. Res. Commun., 1994, 200 (2), 951-957.
190. Ueda, T.; Maekawa, T.; Sadamitsu, D.; Oshita, S.; Ogino, K.; Nakamura, K. The determination of nitrite and nitrate in human blood plasma by capillary zone electrophoresis. Electrophoresis, 1995, 16 (6), 1002-1004.
191. Torre, D.; Ferrario, G.; Speranza, F.; Orani, A.; Fiori, G. P.; Zeroli, C. Serum concentrations of nitrite in patients with HIV-1 infection. J. Clin. Pathol., 1996, 49 (7), 574-576.
192. Van Der Vliet, A.; Eiserich, J. P.; Halliwell, B.; Cross, C. E. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite: A potential additional mechanism of nitric oxide- dependent toxicity. J. Biol. Chem., 1997, 272 (12), 7617- 7625.
193. Westley, J. Rhodanese. Adv. Enzymol. Relat. Areas Mol. Biol., 1973, 39, 327-368.
194. Dastur, D. K.; Quadros, E. V.; Wadia, N. H.; Desai, M. M.; Bharucha, E. P. Effect of vegetarianism and smoking on vitamin B12, thiocyanate, and folate levels in the blood of normal subjects. Br. Med. J., 1972, 3 (821), 260-263.
195. Pettigrew, A. R.; Fell, G. S. Simplified colorimetric determination of thiocyanate in biological fluids, and its application to investigation of the toxic amblyopias. Clin. Chem., 1972, 18 (9), 996-1000.
196. Rehak, N. N.; Cecco, S. A.; Niemela, J. E.; Elin, R. J. Thiocyanate in smokers interferes with the Nova magnesium ion-selective electrode. Clin. Chem., 1997, 43 (9), 1595-1600.
197. Claesson, R.; Granlund-Edstedt, M.; Persson, S.; Carlsson, J. Activity of polymorphonuclear leukocytes in the presence of sulfide. Infect. Immun., 1989, 57 (9), 2776-2781.
198. Laggner, H.; Muellner, M. K.; Schreier, S.; Sturm, B.; Hermann, M.; Exner, M.; Gmeiner, B. M. K.; Kapiotis, S. Hydrogen sulphide: A novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic. Res., 2007, 41 (7), 741-747.
199. Piantadosi, C. A. Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic. Biol. Med., 2008, 45 (5), 562-569.
200. Abu-Soud, H. M.; Hazen, S. L. Interrogation of heme pocket environment of mammalian peroxidases with diatomic ligands. Biochemistry, 2001, 40 (36), 10747-10755.
201. Jain, A. K.; Tewari-Singh, N.; Inturi, S.; Orlicky, D. J.; White, C. W.; Agarwal, R. Myeloperoxidase deficiency attenuates nitrogen mustard-induced skin injuries. Toxicology, 2014, 320, 25-33.
202. Kettle, A. J.; Winterbourn, C. C. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem. Pharmacol., 1991, 41 (10), 1485-1492.
203. Sliskovic, I.; Abdulhamid, I.; Sharma, M.; Abu-Soud, H. M. Analysis of the mechanism by which tryptophan analogs inhibit human myeloperoxidase. Free Radic. Biol. Med., 2009, 47 (7), 1005-1013.
204. Queiroz, R. F.; Vaz, S. M.; Augusto, O. Inhibition of the chlorinating activity of myeloperoxidase by tempol: Revisiting the kinetics and mechanisms. Biochem. J., 2011, 439 (3), 423-431.
205. Rees, M. D.; Bottle, S. E.; Fairfull-Smith, K. E.; Malle, E.; Whitelock, J. M.; Davies, M. J. Inhibition of myeloperoxidasemediated hypochlorous acid production by nitroxides. Biochem. J., 2009, 421 (1), 79-86.
206. Hsuanyu, Y.; Dunford, H. B. Oxidation of clozapine and ascorbate by myeloperoxidase. Arch. Biochem. Biophys., 1999, 368 (2), 413- 420.
207. Meotti, F. C.; Jameson, G. N. L.; Turner, R.; Harwood, D. T.; Stockwell, S.; Rees, M. D.; Thomas, S. R.; Kettle, A. J. Urate as a Physiological Substrate for Myeloperoxidase: Implications for hyperuricemia and inflammation. J. Biol. Chem., 2011, 286 (15), 12901-12911.
208. Chapman, A. L. P.; Mocatta, T. J.; Shiva, S.; Seidel, A.; Chen, B.; Khalilova, I.; Paumann-Page, M. E.; Jameson, G. N. L.; Winterbourn, C. C.; Kettle, A. J. Ceruloplasmin Is an Endogenous Inhibitor of Myeloperoxidase. J. Biol. Chem., 2013, 288 (9), 6465- 6477.
209. Forbes, L. V.; Furtmuller, P. G.; Khalilova, I.; Turner, R.; Obinger, C.; Kettle, A. J. Isoniazid as a substrate and inhibitor of myeloperoxidase: Identification of amine adducts and the influence of superoxide dismutase on their formation. Biochem. Pharmacol., 2012, 84 (7), 949-960.
210. Tiden, A. K.; Sjogren, T.; Svensson, M.; Bernlind, A.; Senthilmohan, R.; Auchere, F.; Norman, H.; Markgren, P. O.; Gustavsson, S.; Schmidt, S.; Lundquist, S.; Forbes, L. V.; Magon, N. J.; Paton, L. N.; Jameson, G. N.; Eriksson, H.; Kettle, A. J. 2- Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J. Biol. Chem., 2011, 286 (43), 37578-37589.
211. Koelsch, M.; Mallak, R.; Graham, G. G.; Kajer, T.; Milligan, M. K.; Nguyen, L. Q.; Newsham, D. W.; Keh, J. S.; Kettle, A. J.; Scott, K. F.; Ziegler, J. B.; Pattison, D. I.; Fu, S.; Hawkins, C. L.; Rees, M. D.; Davies, M. J. Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations. Biochem. Pharmacol., 2010, 79 (8), 1156-1164.
212. Arnhold, J.; Furtmuller, P. G.; Regelsberger, G.; Obinger, C. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur. J. Biochem., 2001, 268 (19), 5142-5148.
213. Jiang, X.; Khursigara, G.; Rubin, R. L. Transformation of lupusinducing drugs to cytotoxic products by activated neutrophils. Science, 1994, 266 (5186), 810-813.
214. Uetrecht, J. P. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev., 1992, 24 (3), 299-366.
215. Davies, B.; Edwards, S. W. Inhibition of myeloperoxidase by salicylhydroxamic acid. Biochem. J., 1989, 258 (3), 801-806.
216. Rich, P. R.; Wiegand, N. K.; Blum, H.; Moore, A. L.; Bonner, W. D. Jr. Studies on the mechanism of inhibition of redox enzymes by substituted hydroxamic acids. Biochim. Biophys. Acta, 1978, 525 (2), 325-337.
217. Davey, C. A.; Fenna, R. E. 2.3 A resolution X-ray crystal structure of the bisubstrate analogue inhibitor salicylhydroxamic acid bound to human myeloperoxidase: A model for a prereaction complex with hydrogen peroxide. Biochemistry, 1996, 35 (33), 10967-10973.
218. Schonbaum, G. R. New complexes of peroxidases with hydroxamic acids, hydrazides, and amides. J. Biol. Chem., 1973, 248 (2), 502- 511.
219. Schonbaum, G. R.; Lo, S. Interaction of peroxidases with aromatic peracids and alkyl peroxides. Product analysis. J. Biol. Chem., 1972, 247 (10), 3353-3360.
220. Forbes, L. V.; Sjogren, T.; Auchere, F.; Jenkins, D. W.; Thong, B.; Laughton, D.; Hemsley, P.; Pairaudeau, G.; Turner, R.; Eriksson, H.; Unitt, J. F.; Kettle, A. J. Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates. J. Biol. Chem., 2013, 288 (51), 36636-36647.
221. Ator, M. A.; David, S. K.; Ortiz de Montellano, P. R. Structure and catalytic mechanism of horseradish peroxidase. Regiospecific meso alkylation of the prosthetic heme group by alkylhydrazines. J. Biol. Chem., 1987, 262 (31), 14954-14960.
222. van Zyl, J. M.; Basson, K.; Uebel, R. A.; van der Walt, B. J. Isoniazid-mediated irreversible inhibition of the myeloperoxidase antimicrobial system of the human neutrophil and the effect of thyronines. Biochem. Pharmacol., 1989, 38 (14), 2363-2373.
223. Burner, U.; Obinger, C.; Paumann, M.; Furtmuller, P. G.; Kettle, A. J. Transient and steady-state kinetics of the oxidation of substituted benzoic acid hydrazides by myeloperoxidase. J. Biol. Chem., 1999, 274 (14), 9494-9502.
224. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology. John Wiley & Sons, Inc.: New York, 1979.
225. Misra, H. P.; Fridovich, I. The oxidation of phenylhydrazine: superoxide and mechanism. Biochemistry, 1976, 15 (3), 681-687.
226. Hallingback, H. R.; Gabdoulline, R. R.; Wade, R. C. Comparison of the binding and reactivity of plant and mammalian peroxidases to indole derivatives by computational docking. Biochemistry, 2006, 45 (9), 2940-2950.
227. Arnhold, J.; Monzani, E.; Furtmuller, P. G.; Zederbauer, M.; Casella, L.; Obinger, C. Kinetics and Thermodynamics of Halide and Nitrite Oxidation by Mammalian Heme Peroxidases. Eur. J. Inorg. Chem., 2006, 2006 (19), 3801-3811.
228. Kettle, A. J.; Candaeis, L. P. Oxidation of tryptophan by redox intermediates of myeloperoxidase and inhibition of hypochlorous acid production. Redox Rep., 2000, 5 (4), 179-184.
229. Middleton, E. Jr.; Kandaswami, C. The Flavonoids, Advances in Research Since 1986. Chapman & Hall: London, 1994.
230. Pandey, K. B.; Rizvi, S. I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev., 2009, 2 (5), 270-278.
231. Magnani, L.; Gaydou, E. M.; Hubaud, J. C. Spectrophotometric measurement of antioxidant properties of flavones and flavonols against superoxide anion. Anal. Chim. Acta, 2000, 411 (1-2), 209- 216.
232. van Acker, S. A. B. E.; Bast, A.; van der Vijgh, W. J. Flavonoids in Health and Diseases. Marcel Dekker: New York, 1998.
233. Camuesco, D.; Comalada, M.; Rodríguez-Cabezas, M. E.; Nieto, A.; Lorente, M. D.; Concha, A.; Zarzuelo, A.; Galvez, J. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. J. Pharmacol., 2004, 143 (7), 908-918.
234. Ocete, M. A.; Galvez, J.; Crespo, M. E.; Cruz, T.; Gonzalez, M.; Torres, M. I.; Zarzuelo, A. Effects of Morin on an Experimental Model of Acute Colitis in Rats. Pharmacology, 1998, 57 (5), 261- 270.
235. Pincemail, J.; Deby, C.; Thirion, A.; de Bruyn-Dister, M.; Goutier, R. Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds. Experientia, 1988, 44 (5), 450-453.
236. Shin, Y. K.; Sohn, U. D.; Choi, M. S.; Kum, C.; Sim, S. S.; Lee, M. Y. Effects of rutin and harmaline on rat reflux oesophagitis. Auton. Autacoid Pharmacol., 2002, 22 (1), 47-55.
237. Zhao, J.; Sharma, Y.; Agarwal, R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion. Mol. Carcinog., 1999, 26 (4), 321-333.
238. Hertog, M. G.; Hollman, P. C. Potential health effects of the dietary flavonol quercetin. Eur. J. Clin. Nutr., 1996, 50 (2), 63-71.
239. Hertog, M. G.; Kromhout, D.; Aravanis, C.; Blackburn, H.; Buzina, R.; Fidanza, F.; Giampaoli, S.; Jansen, A.; Menotti, A.; Nedeljkovic, S.; Pekkarinen, M.; Simic, B. S.; Toshima, H.; Feskens, E. J. M.; Hollman, P. C. H.; Katan, M. B. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med., 1995, 155 (4), 381- 386.
240. Hertog, M. G. L.; Feskens, E. J. M.; Hollman, P. C. H.; Katan, M. B.; Kromhout, D. Dietary flavonoids and cancer risk in the Zutphen elderly study. Nutr. Cancer 1994, 22 (2), 175-184.
241. Hertog, M. G. L.; Feskens, E. J. M.; Kromhout, D.; Hollman, P. C. H.; Katan, M. B. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet, 1993, 342 (8878), 1007-1011.
242. Le Marchand, L.; Murphy, S. P.; Hankin, J. H.; Wilkens, L. R.; Kolonel, L. N. Intake of flavonoids and lung cancer. J. Natl. Cancer Inst., 2000, 92 (2), 154-160.
243. Kawai, Y.; Nishikawa, T.; Shiba, Y.; Saito, S.; Murota, K.; Shibata, N.; Kobayashi, M.; Kanayama, M.; Uchida, K.; Terao, J. Macrophage as a Target of Quercetin Glucuronides in Human Atherosclerotic Arteries: Implication in The Anti-Atherosclerotic Mechanism of Dietary Flavonoids. J. Biol. Chem., 2008, 283 (14), 9424-9434.
244. Kato, Y.; Nagao, A.; Terao, J.; Osawa, T. Inhibition of Myeloperoxidase-catalyzed Tyrosylation by Phenolic Antioxidants in vitro. Biosci. Biotechnol. Biochem., 2003, 67 (5), 1136-1139.
245. Kawai, Y.; Kiyokawa, H.; Kimura, Y.; Kato, Y.; Tsuchiya, K.; Terao, J. Hypochlorous acid-derived modification of phospholipids: characterization of aminophospholipids as regulatory molecules for lipid peroxidation. Biochemistry, 2006, 45 (47), 14201-14211.
246. Momic, T.; Vujcic, Z.; Vasic, V. Kinetics of inhibition of peroxidase activity of myeloperoxidase by quercetin. Int. J. Chem. Kinet., 2008, 40 (7), 384-394.
247. Murota, K.; Terao, J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch. Biochem. Biophys., 2003, 417 (1), 12-17.
248. Day, A. J.; Mellon, F.; Barron, D.; Sarrazin, G.; Morgan, M. R. A.; Williamson, G. Human metabolism of dietary flavonoids: Identification of plasma metabolites of quercetin. Free Radic. Res., 2001, 35 (6), 941-952.
249. Kohnen, S.; Franck, T.; Van Antwerpen, P.; Boudjeltia, K. Z.; Mouithys-Mickalad, A.; Deby, C.; Moguilevsky, N.; Deby-Dupont, G.; Lamy, M.; Serteyn, D. Resveratrol inhibits the activity of equine neutrophil myeloperoxidase by a direct interaction with the enzyme. J. Agric. Food Chem., 2007, 55 (20), 8080-8087.
250. Meotti, F. C.; Missau, F. C.; Ferreira, J.; Pizzolatti, M. G.; Mizuzaki, C.; Nogueira, C. W.; Santos, A. R. Anti-allodynic property of flavonoid myricitrin in models of persistent inflammatory and neuropathic pain in mice. Biochem. Pharmacol., 2006, 72 (12), 1707-1713.
251. Meotti, F. C.; Senthilmohan, R.; Harwood, D. T.; Missau, F. C.; Pizzolatti, M. G.; Kettle, A. J. Myricitrin as a substrate and inhibitor of myeloperoxidase: Implications for the pharmacological effects of flavonoids. Free Radic. Biol. Med., 2008, 44 (1), 109- 120.
252. Schewe, T.; Sies, H. Myeloperoxidase-induced lipid peroxidation of LDL in the presence of nitrite. Protection by cocoa flavanols. Biofactors, 2005, 24 (1-4), 49-58.
253. Buijsse, B.; Feskens, E. J. M.; Kok, F. J.; Kromhout, D. Cocoa intake, blood pressure, and cardiovascular mortality: The Zutphen Elderly Study. Arch. Intern. Med., 2006, 166 (4), 411-417.
254. Heiss, C.; Dejam, A.; Kleinbongard, P.; Schewe, T.; Sies, H.; Kelm, M. Vascular Effects of Cocoa Rich in Flavan-3-ols. J. Amer. Med. Assoc., 2003, 290 (8), 1030-1031.
255. Heiss, C.; Kleinbongard, P.; Dejam, A.; Perre, S.; Schroeter, H.; Sies, H.; Kelm, M. Acute Consumption of Flavanol-Rich Cocoa and the Reversal of Endothelial Dysfunction in Smokers. J. Am. Coll. Cardiol., 2005, 46 (7), 1276-1283.
256. Ogino, T.; Hosako, M.; Hiramatsu, K.; Omori, M.; Ozaki, M.; Okada, S. Oxidative modification of IkappaB by monochloramine inhibits tumor necrosis factor alpha-induced NF-kappaB activation. Biochim. Biophys. Acta, 2005, 1746 (2), 135-142.
257. Ogino, T.; Kobuchi, H.; Sen, C. K.; Roy, S.; Packer, L.; Maguire, J. J. Monochloramine inhibits phorbol ester-inducible neutrophil respiratory burst activation and T cell interleukin-2 receptor expression by inhibiting inducible protein kinase C activity. J. Biol. Chem., 1997, 272 (42), 26247-26252.
258. Omori, M.; Ogino, T.; Than, T. A.; Okada, S. Monochloramine inhibits the expression of E-selectin and intercellular adhesion molecule-1 induced by TNF-alpha through the suppression of NFkappaB activation in human endothelial cells. Free Radic. Res., 2002, 36 (8), 845-852.
259. Kostyuk, V. A.; Kraemer, T.; Sies, H.; Schewe, T. Myeloperoxidase/nitrite-mediated lipid peroxidation of low-density lipoprotein as modulated by flavonoids. FEBS Lett., 2003, 537 (1- 3), 146-150.
260. Kraemer, T.; Prakosay, I.; Date, R. A.; Sies, H.; Schewe, T. Oxidative modification of low-density lipoprotein: Lipid peroxidation by myeloperoxidase in the presence of nitrite. Biol. Chem., 2004, 385 (9), 809-818.
261. (EMA), E. M. A. Assessment report on Gentiana lutea L., radix. 2009; Vol. EMA/HMPC/578322/2008.
262. Lin, C. M.; Chen, C. T.; Lee, H. H.; Lin, J. K. Prevention of cellular ROS damage by isovitexin and related flavonoids. Planta Med., 2002, 68 (4), 365-367.
263. Ozturk, N.; Korkmaz, S.; Ozturk, Y.; Baser, K. H. C. Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from Gentian (Gentiana lutea ssp. symphyandra), on cultured chicken embryonic fibroblasts. Planta Med., 2006, 72 (4), 289-294.
264. Schmieder, A.; Schwaiger, S.; Csordas, A.; Backovic, A.; Messner, B.; Wick, G.; Stuppner, H.; Bernhard, D. Isogentisin-A novel compound for the prevention of smoking-caused endothelial injury. Atherosclerosis, 2007, 194 (2), 317-325.
265. Vieira, T. O.; Seifriz, I.; Charao, C. C. T.; de Oliveira, S. Q.; Creczynski-Pasa, T. B. Antioxidant effects of crude extracts from Baccharis species: inhibition of myeloperoxidase activity, protection against lipid peroxidation, and action as oxidative species scavenger. Rev. Bras. Farmacogn., 2011, 21, 601-607.
266. Leskovac, A.; Joksic, G.; Pasti, I.; Lazarevic-Pasti, T.; Nastasijevic, B.; Petrovic, S. The antiradical, anti-inflammatory and antigenotoxic potential of herbal preparation Chlamyfin. Maced. J. Chem. Chem. En., 2013, 32 (2), 227-237.
267. Lindberg Madsen, H.; Moller Andersen, C.; Viborg Jorgensen, L.; Skibsted, L. H. Radical scavenging by dietary flavonoids. A kinetic study of antioxidant efficiencies. Eur. Food Res. Technol., 2000, 211 (4), 240-246.
268. Diaz, A. M.; Abad, M. J.; Fernandez, L.; Silvan, A. M.; De Santos, J.; Bermejo, P. Phenylpropanoid glycosides from Scrophularia scorodonia: in vitro anti-inflammatory activity. Life Sci., 2004, 74 (20), 2515-26.
269. Konuklugil, B.; Bahadir, O. Phenylpropanoid glycosides from Linum olympicum. Turk. J. Chem., 2004, 28 (6), 741-744.
270. Hwang, Y. P.; Kim, H. G.; Choi, J. H.; Park, B. H.; Jeong, M. H.; Jeong, T. C.; Jeong, H. G. Acteoside inhibits PMA-induced matrix metalloproteinase-9 expression via CaMK/ERK- And JNK/NFkappaB- dependent signaling. Mol. Nutr. Food Res., 2011, 55 Suppl 1, S103-S16.
271. Guvenc, A.; Okada, Y.; Akkol, E. K.; Duman, H.; Okuyama, T.; Calis, I. Investigations of anti-inflammatory, antinociceptive, antioxidant and aldose reductase inhibitory activities of phenolic compounds from Sideritis brevibracteata. Food Chem., 2010, 118 (3), 686-692.
272. Hausmann, M.; Obermeier, F.; Paper, D. H.; Balan, K.; Dunger, N.; Menzel, K.; Falk, W.; Schoelmerich, J.; Herfarth, H.; Rogler, G. In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodiuminduced colitis. Clin. Exp. Immunol., 2007, 148 (2), 373-81.
273. Reinke, D.; Kritas, S.; Polychronopoulos, P.; Skaltsounis, A. L.; Aligiannis, N.; Tran, C. D. Herbal substance, acteoside, alleviates intestinal mucositis in mice. Gastroenterol. Res. Pract., 2015, 2015, 327872.
274. Queiroz, M. L.; Fernandes, M. D.; Valadares, M. C. Neutrophil function in workers exposed to organophosphate and carbamate insecticides. Int. Immunopharmacol., 1999, 21 (4), 263-270.
275. Lazarevic-Pasti, T.; Bondzic, A.; Pasti, I.; Vasic, V. Indirect electrochemical oxidation of organophosphorous pesticides for efficient detection via acetylcholinesterase test. Pestic. Biochem. Physiol., 2012, 104 (3), 236-242.
276. Nauseef, W. M. Insights into myeloperoxidase biosynthesis from its inherited deficiency. J. Mol. Med., 1998, 76 (10), 661-668.
277. Soubhye, J.; Dufrasne, F.; Van, A. P. 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors. WO2010136546 A1, 2010.
278. Eiserich, J. P.; Hristova, M.; Cross, C. E.; Jones, A. D.; Freeman, B. A.; Halliwell, B.; van der Vliet, A. Formation of nitric oxidederived inflammatory oxidants by myeloperoxidase in neutrophils. Nature, 1998, 391 (6665), 393-397.
279. Hazen, S. L.; Zhang, R.; Shen, Z.; Wu, W.; Podrez, E. A.; MacPherson, J. C.; Schmitt, D.; Mitra, S. N.; Mukhopadhyay, C.; Chen, Y.; Cohen, P. A.; Hoff, H. F.; Abu-Soud, H. M. Formation of Nitric Oxid-Derived Oxidants by Myeloperoxidase in Monocytes: Pathways for Monocyte-Mediated Protein Nitration and Lipid Peroxidation In vivo. Circ. Res., 1999, 85 (10), 950-958.
280. Podrez, E. A.; Schmitt, D.; Hoff, H. F.; Hazen, S. L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Investig., 1999, 103 (11), 1547-1560.
281. Sampson, J. B.; Ye, Y. Z.; Rosen, H.; Beckman, J. h. S. Myeloperoxidase and Horseradish Peroxidase Catalyze Tyrosine Nitration in Proteins from Nitrite and Hydrogen Peroxide. Arch. Biochem. Biophys., 1998, 356 (2), 207-213.
282. Shao, B.; Oda, M. N.; Oram, J. F.; Heinecke, J. W. Myeloperoxidase: An oxidative pathway for generating dysfunctional high-density lipoprotein. Chem. Res. Toxicol., 2010, 23 (3), 447-454.
283. Shao, B.; Bergt, C.; Fu, X.; Green, P. S.; Voss, J. C.; Oda, M. N.; Oram, J. F.; Heinecke, J. W. Tyrosine 192 in Apolipoprotein A-I Is the Major Site of Nitration and Chlorination by Myeloperoxidase, but Only Chlorination Markedly Impairs ABCA1-dependent Cholesterol Transport. J. Biol. Chem., 2005, 280 (7), 5983-5993.